BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition
Reuters
Dec 04
BUZZ-Australia's Argenica <a href="https://laohu8.com/S/LENZ">Therapeutics</a> jumps on meeting FDA condition
** Shares of Australia's Argenica Therapeutics AGN.AX surge as much as 34.1% to A$0.295, their highest since November 3
** Biotech firm's lead candidate, a neuroprotective synthetic peptide, ARG-007 did not inhibit the clot dissolving effect of tenecteplase
** The result is one of the key U.S. FDA requirement to lift the clinical hold on Argenica's Investigational New Drug $(IND)$ application for acute ischaemic stroke
** Around 1 mln shares change hands, nearly 7.3x 30-day average
** AGN, YTD down 58.7%
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.singhchundawat@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.